OXIS International, Inc. Announces the Appointment of Dr. Okezie Aruoma as President of Its Scientific Advisory Board
BEVERLY HILLS, Calif., June 23 /PRNewswire-FirstCall/ – OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI), announced today the appointment of Dr. Okezie Aruoma as President of its Scientific Advisory Board.
Dr. Aruoma is considered to be the World’s foremost leading researcher and authority on L-Ergothioneine (ERGO). Dr. Aruoma believes L-Ergothioneine to be the most profound and powerful antioxidant known to science with numerous use applications ranging from the treatment of inflation to combating Alzheimer’s and Parkinson’s disease. He has over 21 years of experience in oxidative stress mechanisms and antioxidant pharmacology. His familiarity with human nutrition and the effects of antioxidants goes hand in hand with Oxis’ primary goal of developing and marketing the highest quality products available to combat and counter-act effects of oxidative stress. His understanding of DNA and free radical science will serve an important function in Oxis’ product development which includes products targeted at heart health, brain health, and resistance against diseases, anti-aging, skin care, inflammation (arthritis, joint pain), liver detoxification and blood sugar regulation.
Dr. Aruoma’s expertise covers food and pharmaceutical safety and regulation, drug delivery based on stem cell biology and pharmaceutical agents which lend potential in providing early diagnostic and preventative treatment for acute diseases with inflammation.
Dr. Aruoma has published ten books, some of which include Molecular Biology of Free Radicals in Human Diseases, DNA & Free Radicals: Techniques, Mechanisms and Applications and Free Radicals in Tropical Diseases. His lecture on “Food Antioxidants and International Health” earned him the Third Goodman Fielder Orator award. He has published over 150 related papers on the effects of free radicals.
Dr. Aruoma is the current Executive Chairman for the Society for Free Radical Research-Africa. He is the Chair of the Pharmacogenetics and Pharmacogenomics Focus Group of the American Association of Pharmaceutical Scientists. He previously served as the first Chair of the Department of Pharmaceutical and Biomedical Sciences.
Dr. Aruoma earned a PhD in Medical Biochemistry from the University of London and his Master’s in Biopharmacy from Chelsea College, London. He was also awarded an MBA in Business administration from the University of Warwick.
Dr. Aruoma is currently a Professor of Pharmaceutical and Biomedical Sciences at the Touro College of Pharmacy in New York.
Sandep Rahi has joined Oxis International as an independent advisor to Oxis. His role will include the task of development of the company’s sales and marketing strategy.
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.
This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company’s filings with the Securities and Exchange Commission.
SOURCE OXIS International, Inc.